Publications by authors named "W W FRYE"

Background: Shared micromobility programs (SMPs) are integral to urban transport in US cities, providing sustainable transit options. Increased use has raised safety concerns, notably about helmet usage among e-scooter and e-bicycle riders. Prior studies have shown that head and upper extremity injuries have risen with SMP adoption, yet data on helmet use remains sparse.

View Article and Find Full Text PDF

Unlabelled: The management of headaches in children and adolescents is still a challenge, with patients experiencing pain for years and polypharmacy. We reviewed the medical history of 31 patients referred to our pain clinic for chronic headaches between April 2023 and April 2024. There were more female than male patients (73%).

View Article and Find Full Text PDF

Pediatric rheumatic diseases (PRDs) are a heterogeneous group of diseases that can have a chronic unpredictable disease course that can negatively affect mood, functioning, and quality of life. Given the range of difficulties faced in managing PRDs, as well as the psychosocial issues youth with these diseases experience, pediatric psychologists can be well suited to address concerns that arise in care for youth with PRDs including adherence, cognitive assessment, pain management, functional disability, and mood. Potential ways that pediatric psychologists can address these concerns and be embedded within an interdisciplinary treatment plan for youth with PRDs are described.

View Article and Find Full Text PDF
Article Synopsis
  • The blood-tumor barrier (BTB) in malignant glioma limits the effectiveness of cytotoxic drugs, and this study investigates how ibrutinib, a drug already approved for lymphoma, impacts BTB function.
  • Ibrutinib was found to dose-dependently reduce brain endothelial cell adhesion and disrupt tight junctions, enhancing penetration of the drug doxil into the tumor and significantly reducing glioma cell viability.
  • The combination of ibrutinib and doxil not only improved drug concentration in the brain but also extended the survival of rodent glioma models, highlighting ibrutinib’s potential to enhance therapeutic efficacy in glioma treatment.
View Article and Find Full Text PDF